Schoenfield Lynn, Jones J Stephen, Zippe Craig D, Reuther Alwyn M, Klein Eric, Zhou Ming, Magi-Galluzzi Cristina
Department of Pathology, Cleveland Clinic, Cleveland, OH, USA.
BJU Int. 2007 Apr;99(4):770-4. doi: 10.1111/j.1464-410X.2006.06728.x. Epub 2007 Jan 16.
To investigate the detection rate and extent of high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands (AG) suspicious for prostate cancer, and the cancer risk in subsequent biopsies, diagnosed by a first 24-core saturation biopsy, as although the optimum extent of biopsy is controversial there is a trend to increase the number of cores taken, and apart from detecting prostate cancer, identifying HGPIN and AG is associated with a greater risk of finding cancer in subsequent biopsies, thus warranting a closer follow-up.
The study included 100 men with consecutive first-time saturation biopsies; the indications for biopsy were an abnormal digital rectal examination and/or a serum prostate-specific antigen (PSA) level of >2.5 ng/mL. Each biopsy specimen was reviewed retrospectively by two pathologists to confirm the histological diagnosis. The number and percentage of cores positive for HGPIN, bilateral involvement and multifocality (HGPIN involving two or more cores) were recorded in each case. The presence of AG and cancer was also recorded. An extended (10-12 cores) repeat biopsy was available in 23 patients.
The median (range) age and PSA level of the patients was 63 (41-80) years and 4.9 (1.5-67.0) ng/mL, respectively. Of the 100 patients, 34% had normal findings (benign prostatic tissue, BPT), 39% had cancer, 26% had HGPIN and cancer, 22% had HGPIN alone, and 5% had AG. Repeat biopsies were available in nine of the 22 (41%) patients with HGPIN, four of five with AG, and 10 of the 34 (29%) with BPT. The median (range) interval between the first and second biopsy was 13 (4-36) months. Prostate cancer was detected at the second biopsy in a third of patients with isolated HGPIN on the first biopsy, and one of the four with AG. None of the patients with BPT had cancer on re-biopsy. The cancer detection rate was significantly greater in patients with multifocal than in those with unifocal HGPIN (80% vs none, P = 0.010). The median number of cores and percentage of tissue involved by HGPIN was 3.5 (2-5) and 1.0 (0.5-1.2)%, respectively, in patients with cancer detected in repeat biopsies, compared to 1.0 (1-3) and 0.2 (0.2-0.6)% in patients without cancer on repeat biopsy (P = 0.023 and 0.015, respectively).
Identifying multifocal HGPIN on first saturation biopsy is associated with an overall cancer detection rate of 80% on repeat 10-12-core biopsy. Although there were few patients, the detection of multifocal HGPIN warrants additional searches for concurrent invasive carcinoma by repeated biopsy.
通过首次24针饱和穿刺活检来研究高级别前列腺上皮内瘤变(HGPIN)及可疑前列腺癌的非典型腺管(AG)的检出率和范围,以及后续活检中的癌症风险。尽管活检的最佳范围存在争议,但活检针数有增加的趋势,并且除了检测前列腺癌外,识别HGPIN和AG与后续活检中发现癌症的风险增加相关,因此需要密切随访。
本研究纳入了100例连续接受首次饱和穿刺活检的男性;活检指征为直肠指检异常和/或血清前列腺特异性抗原(PSA)水平>2.5 ng/mL。两名病理学家对每个活检标本进行回顾性检查以确认组织学诊断。记录每种情况下HGPIN阳性的针数及百分比、双侧受累情况和多灶性(HGPIN累及两个或更多针)。还记录了AG和癌症的存在情况。23例患者可进行扩大(10 - 12针)重复活检。
患者的年龄中位数(范围)和PSA水平分别为63(41 - 80)岁和4.9(1.5 - 67.0)ng/mL。100例患者中,34%检查结果正常(良性前列腺组织,BPT),39%患有癌症,26%患有HGPIN和癌症,22%仅患有HGPIN,5%患有AG。22例(41%)患有HGPIN的患者中有9例可进行重复活检;5例患有AG的患者中有4例;34例(29%)患有BPT的患者中有10例。首次和第二次活检之间的间隔时间中位数(范围)为13(4 - 36)个月。在首次活检时孤立性HGPIN的患者中,三分之一在第二次活检时检测到前列腺癌,4例患有AG的患者中有1例。BPT患者再次活检时均未发现癌症。多灶性HGPIN患者的癌症检出率显著高于单灶性HGPIN患者(80%对无,P = 0.010)。在重复活检中检测到癌症的患者中,HGPIN累及的针数中位数和组织百分比分别为3.5(2 - 5)和1.0(0.5 - 1.2)%,而在重复活检中未发现癌症的患者中分别为1.0(1 - 3)和0.2(0.2 - 0.6)%(分别为P = 0.023和0.015)。
在首次饱和穿刺活检中识别多灶性HGPIN与重复10 - 12针活检时80%的总体癌症检出率相关。尽管患者数量较少,但检测到多灶性HGPIN需要通过重复活检进一步寻找同时存在的浸润性癌。